Y-mAbs is a commercial-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. We have a broad and advanced product pipeline, including pivotal-stage product candidates against a range of targets. Our mission is to become the world leader in developing better and safer antibody-based oncology products addressing clear unmet pediatric and adult medical needs. With the right partnerships and collaborations, we envision changing the course of cancer care and its outcomes.
Looking for a particular Y-mAbs Therapeutics, Inc. employee's phone or email?
Y-mAbs Therapeutics, Inc. Questions
The Y-mAbs Therapeutics, Inc. annual revenue was $84.6 million in 2026.
Joris Wilms is the SVP, Chief Operating Officer of Y-mAbs Therapeutics, Inc..
47 people are employed at Y-mAbs Therapeutics, Inc..
Y-mAbs Therapeutics, Inc. is based in New York, New York.
The NAICS codes for Y-mAbs Therapeutics, Inc. are [5413, 54138, 54, 32, 541, 325].
The SIC codes for Y-mAbs Therapeutics, Inc. are [28, 283].
Top Y-mAbs Therapeutics, Inc. Employees
-
5+
-
Sharif Koep
Global Medical Affairs Director at Y-mAbs Therapeutics, Inc.
Minneapolis, MN, US11 -
12
-
23
-
5+5+
Related Companies
